// App-Quantinova.ai

1282 : Combination of PI3K targeting with cetuximab and irradiation: a preclinical study on an orthotopic xenograft model of head and neck cancer

Researchers

Presenter

  • Gerard Milano

Principal Investigators

  • Alexandre Bozec

  • Nathalie Ebran

Medical Centers

  • Centre Antoine-Lacassagne, Nice, France

Locations

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Squamous cell carcinoma of the head and neck

  • Solid malignancies

Biomarkers

  • Phosphatidylinositol 3-kinase

  • Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform

  • Serine/threonine-protein kinase mTOR

  • PI3K/AKT

Drug/Treatment

  • buparlisib

  • Erbitux

  • BKM-120

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved